Pharmaceutical Executive-10-01-2015

Pharmaceutical Executive
Features

October 16, 2015

Medicine is entering a new era of “gene editing.” Instead of simply being able to “read” our genes, practitioners will be able to adapt and modify DNA sequencing in living cells to treat, cure, and even prevent disease. Defective genes responsible for life-threatening diseases can be rendered harmless by gene editing; it can also be used to develop new, precisely targeted biological drugs based on an individual’s distinct genetic markers. The full list of possibilities, in every area of the life sciences, is simply beyond imagination.

Pharmaceutical Executive

Driven by knowledge advances and the importance of a more collaborative commercial model, intellectual property (IP) has morphed from an arcane, specialized function dominated by technicians to a showcase strategic priority of the “c-suite.” This trend is hardly restricted to the life sciences. In fact, some of the most creative work in using IP tools to extract more value from knowledge assets is taking place among businesses that operate across multiple sectors.

Pharmaceutical Executive

For years, many companies have competed to demonstrate that their products could achieve the holy grail in type 2 diabetes (T2D): cardiovascular (CV) risk reduction. According to the American Diabetes Association, pharma companies to date have spent over $2 billion and tested 138,000 patients in company-sponsored CV-risk reduction T2D trials, including the recent large-scale TECOS, SAVOR, EXAMINE, and ELIXA studies. 

Pharmaceutical Executive

With next month designated National Alzheimer’s Disease and Awareness Month in the US, Julian Upton looks at the film star whose plight pushed the long-misunderstood disorder into the spotlight.

Pharmaceutical Executive
From the Editor

October 08, 2015

A new and more compelling strategy must be crafted to engage critics on drug pricing and bolster biopharmaceuticals as a leader in technological innovations that lower health costs overall.

Pharmaceutical Executive

In the midst of a leadership vacuum at the European Medicines Agency, Pharm Exec talks with the organization’s top medical officer, Hans-Georg Eichler, about its potentially game-changing drug approval program-one designed to balance safety requirements with faster patient access to the strong science now emerging from industry labs.

Columns
Pharmaceutical Executive

October 07, 2015

Managing the nomination of new FDA commissioner adds to packed agenda

Pharmaceutical Executive

The rising focus on difficulties in swallowing tablets spells a big opportunity for pharma.

Pharmaceutical Executive

Adoption of joint procurement agreement signals new effort from EU to better understand drug pricing issues.

Pharmaceutical Executive
Special Sponsored Section

October 01, 2015

After several years on the back burner, Romania’s pharmaceutical sector appears to be enjoying a resurgence-one it hopes will catapult the country’s healthcare system on a path to sustainability over the long haul.